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Abstract
Background: Antibodies against citrullinated proteins (ACPA) are common in patients with rheumatoid arthritis (RA).
ACPA can appear before disease onset and target many self-antigens. Citrullinated fibrin/fibrinogen represents a
classical ACPA target antigen, and mass spectrometry of RA synovial fluid reveals elevated citrullinated (cit) fibrinogen
(Fib) peptides compared to non-RA controls. We investigated the extent to which these less-studied peptides
represent autoantibody targets and sought to visualize the corresponding cit-Fib-reactive B cells in RA patients.
Methods: An in-house ELISA was established against four cit-Fib α-subunit peptides (cit-Fib α-35; cit-Fib α-216,218;
cit-Fib α-263,271 and cit-Fib α-425,426) and serum from patients with established RA (n = 347) and disease controls
with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) (n = 236) were analyzed. RA patients were genotyped for
HLA-DR alleles, PTPN22 R620W and screened for anti-CCP2 and cit-Fib protein antibodies. The cit-Fib peptides were
also used to assemble antigen tetramers to identify cit-Fib-reactive B cells in peripheral blood by flow cytometry.
Results: The frequencies of autoantibodies against different cit-Fib epitopes in RA patients compared to PsA/AS
patients were: cit-Fib α-35 (RA 20%, vs PsA/AS 1%); cit-Fib α-216,218 (13% vs 0.5%); cit-Fib α-263,271 (21% vs 0.5%) and
cit-Fib α-425,426 (17% vs 1%). The presence of autoantibodies against these peptides was associated with presence of
anti-CCP2 and anti-cit-Fib protein antibodies. No association was found between HLA-DR shared epitope and
antibodies to the different cit-Fib peptides. However, association was observed between the PTPN22 risk allele and
positivity to cit-Fib α-35 and cit-Fib α-263,271. B cells carrying surface Ig reactive to these cit-Fib peptides were found in
RA peripheral blood and these tend to be more common in PTPN22 risk allele carriers.
Conclusions: Our data show that several cit-Fib peptides are targeted by autoantibodies in RA, but not in PsA/AS,
implicating that these are not due to arthritis but more specific for RA etiology. The RA-associated anti-cit protein
response is broad with many parallel immune responses. The association between cit-Fib autoantibodies and the
PTPN22 R620W risk allele supports the hypothesis of altered B cell regulation, such as autoreactive B cells evading
tolerance checkpoints.
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Background
Autoantibodies against citrullinated proteins (ACPA) are
specifically associated with rheumatoid arthritis (RA) and
are present prior to the onset of the disease [1, 2]. ACPA-
positive patients are more likely to suffer from a severe
form of the disease with enhanced radiological progression
[3]. The core feature of epitopes recognized by ACPA is
the non-coding amino acid citrulline (Cit). Accordingly,
synthetic (cyclic) citrullinated peptides (CCP) are often
used in highly sensitive and specific commercial ELISA
kits to detect ACPA [4, 5]. ACPA recognize a variety of
citrullinated antigens - prominent among them being
citrullinated α-enolase, vimentin, type II collagen, fibrino-
gen and histone [6, 7].
Fibrinogen, a hexameric molecule containing pairs of α,
β and γ chains, is the precursor of fibrin and is involved in
the clotting cascade [8]. Citrullinated fibrinogen (cit-Fib)
is known to be present in the synovial fluid of patients
with RA and autoantibodies against cit-Fib are found both
in the sera and synovial fluid of patients with RA [8–10].
Anti-cit-Fib ELISA has been suggested to display similar
diagnostic performance to the commercial anti-CCP
ELISA [11, 12].
The exact pathophysiological involvement of cit-Fib and
anti-cit-Fib antibodies is not fully understood, but there
are several indications that they may have a pathogenic
role in RA. For instance, it has been demonstrated that
immunization of HLA-DR4-IE transgenic mice with cit-
Fib results in the induction of (mild) disease symptoms
characteristic of RA [13]. Circulating immune complexes
containing cit-Fib have been found in patients with RA
and these immune complexes have been shown to stimu-
late macrophages to produce TNF-α via the Fcγ receptor
and Toll-like receptor 4 in vitro [14, 15]. Fibrinogen has
81 arginine residues of which two thirds are susceptible to
citrullination, although most of these sites do not serve as
B cell epitopes [16]. Several studies have identified and
validated some of the cit-Fib epitopes in RA using
different approaches [8, 16–20]. Cit-Fib has also been
verified as an ACPA target in patients with RA throughout
the world [21–23] with recognition of the α subunit
peptide 36-52 and the β subunit peptide 60-74 being the
most prominent.
This study is based on the cit-Fib peptides previously
identified via mass spectrometry of RA synovial fluid [24],
focusing on the immune reactivity against these less-
studied peptides. Using synthetic peptides derived from
cit-Fib, we established ELISAs to analyze serum from
healthy individuals, patients with RA and patients with
non-RA conditions, for the presence of autoantibodies
against some of the cit-Fib epitopes. The association be-
tween these autoantibodies and the two most prominent
genetic RA risk factors, HLA-DR shared epitope (SE) al-
leles and the PTPN22 R620W allele coding for a tyrosine
phosphatase variant, was investigated. Finally, anti-cit-Fib-
specific B cells in the peripheral blood of patients with RA
were characterized and the association with the aforemen-
tioned risk alleles was investigated.
Methods
Patients and healthy subjects
Serum samples were collected from 347 patients diag-
nosed as having established RA according to the ACR
criteria [25]. All patients attended the Rheumatology
unit at the Karolinska University Hospital, Stockholm,
Sweden, where the serum samples were collected and
stored at -80 °C until further use. All the samples were
previously assayed for anti-CCP2 antibodies and anti-
bodies against full cit-Fib (cit-Fib protein) [10]. Add-
itionally, serum samples from 152 healthy subjects and
236 patients with psoriatic arthritis (PSA) or ankylosing
spondylitis (AS) were included as healthy and disease
controls, respectively (Table 1). The ethical review board
of Karolinska University hospital approved this study
and all the patients involved gave informed consent.
HLA-DR and PTPN22 genotyping
A total of 326 of the 347 patients with RA were previ-
ously genotyped for the HLA-DR SE allele [6] and 322
of the 347 patients with RA were genotyped for the
PTPN22 R620W risk allele [26]. HLA-DRB1*0101,
*0102, *0401, *0404, *0405 or *1001 alleles were classi-
fied as HLA-shared epitope (HLA-SE) alleles [27].
ELISA for the detection of IgG against different cit-Fib
peptides
Biotinylated Fib peptides (Table 2) were synthesized by a
solid-phase procedure using fluorenylmethoxycarbonyl
(Fmoc) chemistry as described previously [28]. The pep-
tides were at least 90% pure as deduced from their elu-
tion pattern on reversed-phase high performance liquid
chromatography (HPLC). Streptavidin-coated high bind-
ing capacity 96-well ELISA plates (Thermo Scientific)
were coated with the peptides in their native and citrulli-
nated forms at a concentration of 2.5 μg/ml in coating
buffer (0.05% Tween-20, 0.1% bovine serum albumin
(BSA), Tris-buffered saline). The plates were washed
Table 1 Characteristics of the patients in the different groups
Healthy Disease controls Patients with RA
Number of individuals 152 236 347
Female), n (%) 107 (70.4) 115 (48.7) 277 (79.8)
Age, median (range) 57 (23–71) 47 (18–85) 58 (21 − 94)
Anti-CCP2, n (%) 5 (3.3) 10 (4.2) 250 (72.0)
Anti-cit-Fib protein,
n (%)
NA NA 190 (54.9)
RA rheumatoid arthritis, CCP cyclic citrullinated peptides, cit-Fib citrullinated
fibrinogen, NA data not available
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with PBS containing 0.05% Tween-20 after every incuba-
tion step. For detection of the antibodies against citrulli-
nated peptides, the serum samples were diluted 1:100 in
radioimmunoassay (RIA) buffer (1% BSA, 350 mM NaCl,
10 mM Tris HCl, pH 7.6, 1% (v/v) Triton X-100, 0.5%
(weight/volume) sodium deoxycholate, 0.1% sodium do-
decyl sulfate). The bound antibodies were detected with
horseradish peroxidase-conjugated goat anti-human IgG
F(ab’)2 (Jackson Immuno Research). Bound antibodies
were visualized using the chromogenic substrate
3,3′,5,5′-tetramethylbenzidine (TMB, Sigma-Aldrich).
The optical density (OD) was then measured at 450 nm
with reference at 650 nm subtracted. A standard curve
was included in each plate to convert the OD values into
arbitrary units.
The cutoff value for each of the citrullinated antigens
was set to the 98th percentile of values from healthy sub-
jects (n = 152). In some cases, samples displayed high re-
activity to both a citrullinated peptide and to its native
arginine-containing counterpart, thereby distorting the
analysis. Therefore, a ratio between the OD values ob-
tained with the peptides containing arginine and citrul-
line was determined for each sample and samples with a
ratio greater than 0.8 were considered negative.
Tetramer production and flow cytometry
The B cell antigen tetramer consists of an R-phycoerythrin
(PE)-labeled streptavidin (SA) core and four identical bio-
tinylated peptides. Tetramers were prepared as previously
described [29]. Briefly, the biotinylated cit-Fib peptides used
in the ELISA were incubated with SA-PE (Prozyme) at a
molar ratio of 10:1. The tetramer fraction was then purified
using a 100-kD molecular weight cutoff Amicon Ultra filter
(Millipore). The molarity of the tetramer was calculated
with the supplier-determined ratio of SA to PE, after
measuring the concentration of PE by Nanodrop (Thermo
Fischer). The decoy tetramer was prepared, as described
above, by incubating the biotinylated native (non-citrulli-
nated) Fib peptides with SA-PE pre-conjugated to Alexa
Flour 647 (Molecular Probes Invitrogen). The four α-chain
derived Fib peptides were assembled as tetramers separately
and then pooled at the time of sample staining. The decoy
tetramers were assembled and used in the same manner
with the corresponding native Fib peptides.
Tetramer-positive B cells were analyzed in two small co-
horts of patients with RA, selected/recruited based on their
PTPN22 risk allele status (CC - non risk vs CT - risk). The
pilot cohort consisted of cryopreserved peripheral blood
mononuclear cells (PBMC) (n = 5 individuals, all female,
median age 49 (range 40–75), all HLA-DR SE-negative)
and the validation cohort consisted of fresh PBMC (n = 10
individuals, 7 female/3 male, median age 58 (range 30–69),
all HLA-DR SE-positive). PBMC isolated from patients
were stained with the decoy and cit-Fib tetramers in buffer
containing Fc blocking solution (FcR Blocker Miltenyi Bio-
tec), then passed over a magnetized LS column (Miltenyi
Biotec) to enrich for tetramer-binding cells. Both the bound
and flow-through fractions were stained with APC-H7-
labeled anti-CD3 (SK7), APC-H7-labeled anti-CD14
(MφP9), APC-H7-labeled anti-CD16 (3G8), BV421-labeled
anti-CD19 (HIB19), V500-C-labeled anti-CD20 (L27), PE-
Cy7-labeled anti-CD27 (M-T271) and FITC-labeled anti-
IgD (IA6-2) (all antibodies from BD Biosciences). All the
incubation and wash steps were performed using MACS
buffer containing 1 mM EDTA and 0.5% BSA in PBS.
Flow cytometry was performed using a 4-laser
(405 nm, 488 nm, 561 nm and 640 nm) LSR Fortessa
(BD Biosciences) and analyzed with FlowJo software
(Tree Star). Fluorescent AccuCheck counting beads
(Invitrogen) were used to calculate total numbers of live
lymphocytes in the column-bound and flow-through
suspensions. The gating strategy for tetramer staining
was based on a forward scatter (FSC)/side scatter (SSC)
lymphocyte gate and removal of doublets followed by
dumping CD3, CD14 and CD16 as depicted in Fig. 3a,
before focusing on the B cell subset.
Statistical analysis
All statistical analyses were carried out using GraphPad
Prism (version 6.0) software, SPSS software and Microsoft
Excel 2010. Chi square analysis (or Fisher’s exact test
when appropriate) was performed to analyze the associ-
ation between the presence of antibody against the cit-Fib
peptides and anti-CCP2 antibodies, antibodies against
citrullinated full-length Fib (cit-Fib protein), and HLA-SE
and PTPN22 risk alleles. P values less than 0.05 were
considered significant and have not been corrected for
multiple comparisons.
Results
Antibodies against the different citrullinated fibrinogen
peptides are present in the serum of patients with RA
Using mass spectrometry analysis [24], fibrinogen
peptides containing the citrulline sites α-35, α-263,271
and α-425,426 had a spectral count 2.5 times higher
than controls and were present in the synovial fluid of
more patients with RA than controls. All the peptides
had a Mascot score greater than 40 and have also been
Table 2 Sequence of the different fibrinogen alpha peptides in
their citrullinated form used in the ELISA
Peptide Amino acid Peptide sequence
Cit-Fib α 35 29-41 AEGGGV(Cit)GPRVVEZO
Cit-Fib α 216,218 201-225 KDLLPS(Cit)D(Cit)QHLPLIKZO
Cit-Fib α 263,271 256-278 QMRMELE(Cit)PGGNEIT(Cit)GGSTSYGZO
Cit-Fib α 425,426 419-432 NVSPGT(Cit)(Cit)EYHTEKZO
O biotin, Z 6-aminohexanoic acid
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identified by in-vitro citrullination of fibrinogen using
human and rabbit PAD enzymes (summarized in [16]).
To assess the detailed anti cit-Fib B cell responses, we
used ELISA to test for the presence of antibodies against
the four different cit-fibrinogen peptides [16, 24]. A co-
hort of healthy subjects was used to determine the cutoff
at the 98th percentile for the ELISA and based upon this
cutoff, the cit-Fib reactivity in serum from 347 patients
with RA was analyzed. We found relatively weak, though
frequently present, reactivity in the RA cohort, with
20.2% towards the cit-Fib α-35, 12.5% towards cit-Fib
α-216,218, 21.0% towards cit-Fib α-263,271 and 17.0%
towards cit-Fib α-425,426 (Fig. 1).
Antibodies against the different citrullinated fibrinogen
peptides are specific for RA
To understand if the presence of antibodies against
these cit-Fib targets were specific for RA, we then
analyzed serum from a cohort of patients with non-RA
arthritis. For this purpose, we analyzed serum from a
cohort of 236 patients with PSA and AS: we only
identified a few reactive serum samples, mostly with
low levels of the different antibodies. Reactivity against
the cit- Fib α-35, cit- Fib α-216,218, cit- Fib α-263,271
and cit- Fib α-425,426 in this cohort was found to be
1.0% (n = 2), 0.5% (n = 1), 0.5% (n = 1) and 1.0% (n = 2),
respectively (Fig. 1).
Anti-cit-Fib reactivity is predominantly non-overlapping
With regard to overlap between the different epitope re-
activity, i.e. whether the same patients presented with
more than one anti-cit-Fib antibody, and to the distribu-
tion compared to anti-CCP2, we observed that most pa-
tients were reactive to a single cit-Fib peptide, although
some overlap was seen (Fig. 2). Still, the cit-Fib response
was predominantly in the anti-CCP2-positive patient
subset (p < 0.0001).
Association of anti-cit-Fib with PTPN22 R620W risk allele
It has been previously shown that the presence of ACPA
is associated with the HLA-DR SE alleles and with the
PTPN22 R620W risk allele [30]. We examined the asso-
ciation between these two genotypes and antibodies
against the four cit-Fib peptides, antibodies against
whole cit-Fib protein and anti-CCP2 antibodies. The as-
sociation was significant (p ≤ 0.05) for antibodies against
the four cit-Fib peptides and anti-CCP2 antibodies
(Table 3). Also a significant association was observed
between the presence of antibodies against all cit-Fib
peptides and those against whole cit-Fib protein. No
association was observed between the presence of anti-
bodies against any of the cit-Fib peptides and HLA-DR
SE. In contrast, an association was observed between the
PTPN22 risk allele and seropositivity for cit-Fib α-35
and cit-fibrinogen α-263,271 (Table 3). PTPN22 risk
allele carriers had a significant odds ratio ( (OR) 95% CI)
for the presence of antibodies against cit-Fib α-35, OR = 1.8
(1.0–3.1) and cit-Fib α-263,271, OR = 2.0 (1.1–3.4)
(Table 4).
Visualization of cit-Fib-reactive B cells by tetramer
technology
Based on data suggesting a role for PTPN22 in the nega-
tive selection of autoreactive B cells [31], we hypothe-
sized that PTPN22 risk allele carriers in our cohort may
have an expanded population of cit-Fib reactive B cells
relative to non-risk allele carriers. To test this, we con-
structed B cell antigen tetramers for quantification and
comparison of tetramer-positive B cells in PTPN22 risk
allele non-carrier (CC) and carrier (CT, TT) patients
with RA. Only CD19+ CD20+ B cells were included in
the tetramer analyses (Fig. 3a). Analysis of frozen PBMC
from five patients with RA (three CC and two CT)
showed a trend in increased frequency of tetramer-
positive B cells in the patients carrying the PTPN22 risk
allele (Fig. 3b). To validate this finding, we recruited ten
A B C D
Fig. 1 Levels and percentage reactivity of serum antibodies against the different citrullinated fibrinogen (cit-Fib) peptides. Comparison of the
levels of antibodies against the four different cit-Fib peptides in serum from patients and controls (a. cit-Fib α35; b. cit-Fib α216;218; c. cit-Fib
α263, 271; d. cit-Fib α425, 426). Horizontal dotted line indicates the ELISA cutoff for positivity towards the cit-peptide. Pie charts (bottom) represent
the percentage positivity in each cohort. Number of individuals is indicated in the centre of the pie chart. RA rheumatoid arthritis
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AB
Fig. 2 Serum reactivity to multiple citrullinated fibrinogen (cit-Fib) epitopes. a. Pie charts indicate the proportion of serum samples that were reactive
with multiple cit-Fib peptides. The total number of individuals is indicated in the centre of the pie chart. The p value indicates the result from a chi
square test comparing the multiple reactivates in anti-citrulline protein antibody (ACPA)-positive vs ACPA-negative individuals. b. Illustration of the
multiple reactivity seen in individuals positive for antibodies against each cit-Fib peptide. CCP cyclic citrullianted peptides
Table 3 Associations between cit-Fib reactivity and serological (anti CCP2 and anti-cit-Fib) and genetic risk markers (HLA-DR SE and
PTPN22 risk allele)
All
patients
(n = 347)
Anti CCP2 (n = 347) Anti-cit-Fib (n = 346)
No Yes P value No Yes P value
Cit-Fib α 35 70 (20.2) 0 (0) 70 (28.0) <0.0001 3 (1.9) 66 (34.74) <0.0001
Cit-Fib α 216,218 44 (12.7) 2 (2.1) 42 (16.8) 0.0001 13 (8.3) 31 (16.32) 0.03
Cit-Fib α 263,271 73 (21.0) 1 (1.0) 72 (28.8) <0.0001 8 (5.1) 64 (33.68) <0.0001
Cit-Fib α 425,426 59 (17.0) 2 (2.1) 57 (22.8) <0.0001 14 (9) 45 (23.68) 0.0003
Reactivity to at least one cit-Fib peptide 168 (48.4) 3 (3.1) 165 (66.0) <0.0001 29 (18.6) 138 (72.63) <0.0001
HLA-DR SE (n = 326) PTPN22 C1858T (n = 322)
Cit-Fib α 35 70 (20.2) 11 (15.1) 55 (21.74) 0.21 38 (17.4) 28 (27.18) 0.04
Cit-Fib α 216,218 44 (12.7) 12 (16.4) 30 (11.86) 0.30 32 (14.8) 9 (8.74) 0.14
Cit-Fib α 263,271 73 (21.0) 13 (17.8) 57 (22.53) 0.39 39 (17.8) 30 (29.13) 0.02
Cit-Fib α 425,426 59 (17.0) 10 (13.7) 46 (18.18) 0.37 34 (15.5) 23 (22.33) 0.14
Reactivity to at least one cit-Fib peptide 168 (48.4) 34 (46.6) 124 (49.01) 0.71 99 (45.2) 58 (56.31) 0.06
Anti-cit Fib protein 190 (54.9) 29 (40.3) 147 (58.1) 0.01 106 (48.6) 69 (67.0) 0.003
Data represent the numbers (percentage) and p values (uncorrected for multiple comparisons). Cit-Fib citrullinated fibrinogen, CCP cyclic citrullinated peptides, SE
shared epitope
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additional patients with RA (five CC and five CT
PTPN22 allele carriers) and found a similar trend for
tetramer-positive B cells with individuals carrying the
PTPN22 risk allele (Fig. 3c).
Discussion
Citrullination of proteins is a posttranslational modifica-
tion that in susceptible individuals may lead to immune
activation, autoantibody production and eventually
development of RA [22]. Detection of these antibodies is
generally performed with commercial kits developed as
diagnostic tools to catch a large array of ACPA specific-
ities. Growing evidence however indicates that a more re-
fined characterization of the ACPA response is needed to
define disease subgroups with distinct clinical phenotypes
and genetic associations [32]. Here, we characterized
Table 4 Table shows the odds ratio of reactivity against different cit-Fib peptides and genetic risk allels in RA (HLA-DR SE and
PTPN22 risk allele)
Cit-Fib α 35 Cit-Fib α 216,218 Cit-Fib α 263,271 Cit-Fib α 425,426 Cit-Fib protein
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
SE 1.6 (0.8–3.2) 0.21 0.7 (0.3–1.4) 0.31 1.3 (0.7–2.6) 0.39 1.4 (0.7–2.9) 0.37 2.1 (1.2–3.5) 0.008
PTPN22 1.8 (1–3.1) 0.04 0.6 (0.3–1.2) 0.14 2.0 (1.1–3.4) 0.02 1.6 (0.9–2.8) 0.14 2.1 (1.3–3.5) 0.002
cit-Fib citrullinated fibrinogen, RA rheumatoid arthritis, SE shared epitope
A
B C
Fig. 3 B cell antigen tetramer analysis in individuals with PTPN22 risk allele. a. Gating strategy for identification of citrullinated fibrinogen (cit-Fib) (pooled
tetramers from four α-chain-derived Fib peptides) reactive B cells from peripheral blood mononuclear cells (PBMC). Cells were gated on forward scatter /side
scatter to select for lymphocytes and removal of doublets followed by dumping of CD3+ CD14+ and CD16+ cells. All remaining tetramer analysis was
performed on CD19+ CD20+ B cell subsets. b. Cit-Fib tetramer analysis in PBMC (frozen) from 5 patients with rheumatoid arthritis (RA), who served as a pilot
cohort. CC PTPN22 risk allele non-carriers, CT risk carriers. Median difference between the two groups was not statistically significant. c. Cit-Fib tetramer analysis
in PBMC (fresh) from 10 patients with RA, who served as a validation cohort. Median difference between the two groups was not statistically significant
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serum reactivity against four cit-Fib peptides originally
identified by mass-spectrometry analysis of RA synovial
fluid. The patient samples represented long-standing RA
in need of joint effusions, and as a clinical comparison we
used serum samples from equally long-standing psoriatic
or spondyloarthritis at time points when patients under-
went joint effusions. Antibodies against these citrullinated
peptides were specific for RA and show distinct genetic
association with PTPN22 but not HLA-SE risk alleles.
The data generated represent established RA, and earlier
disease stages were not analyzed in the present study.
Citrullinated fibrinogen is one of the first and most well-
characterized autoantigens in RA [33]. During the last few
years, several new citrullinated proteins have been identified
and added to the growing list of potential autoantigens in
RA [34–38]. Fibrinogen is elevated in the serum of patients
with RA compared to controls [39] and elevated cit-Fib that
is citrullinated on fibrin(ogen) has been identified using
different techniques, and some of them have been shown
to contain ACPA-targeted epitopes [8, 17–19, 40]. Using
unbiased mass spectrometry, we have previously identified
several cit-Fib peptides as potential antigenic epitopes in
RA [24]. We were able to identify serum autoantibodies
directed against these citrullinated peptides in patients
with RA but not in other types of chronic inflammatory
joint disease.
Identification of multiple distinct B cell epitopes
recognized by the immune system suggests that loss of B
cell tolerance towards cit-Fib might play an important
role in development of the disease. The antibody reactiv-
ity in the present study was relatively less frequent, but
was confined to the seropositive (CCP) RA and provides
an addition to the growing family of ACPAs. Their low
frequency excludes the possibility of substantiating any
clinical and pathological importance at this stage, but
instead sheds light on the dysregulated B cell compart-
ment in seropositive RA. A limitation of our study is
related to exclusion of those samples reacting with the
native peptide that might result in underestimation of
the real frequency of these antibodies in patients with
RA. This dual reactivity to native and citrullinated self--
antigen could indeed be biologically significant and rele-
vant to RA pathogenesis. Further analysis is needed in
order to clarify this issue.
Previous reports have shown that antibodies against cit-
vimentin and cit-α-enolase and to a lesser extent cit-Fib are
associated with presence of HLA-DR shared epitope [22].
We were not able to identify any association between auto-
antibody reactivity towards our fibrinogen peptides and the
HLA-DR shared epitope. Taken together, these data may
suggest that ACPA towards some cit-Fib antigens might
not arise via classical T cell help to autoreactive B cells, but
instead in a more innate or T cell independent fashion. In
this context it has been demonstrated that the autoimmune
risk allele PTPN22 promotes survival of autoreactive B cells
in both RA and type-1 diabetes mellitus by evading the
tolerance checkpoints [31, 41, 42].
More recently, PTPN22 and TNF receptor-associated
factor (TRAF)3 have been put forward as inhibitors of
IL-6R signaling in B cells and plasma cell differentiation
[43]. It is intriguing to think that the functional
polymorphism in PTPN22 could influence this pathway.
Obviously, the association between PTPN22 and the
autoantibodies we study could also be indirect; the
PTPN22 risk allele has been extensively studied in T cell
function and could influence the number of follicular
helper T cells, which could subsequently increase B cells
and antibody production, as demonstrated in mice [44].
We observed association between the PTPN22 risk allele
and autoantibodies against two of the cit-Fib epitopes,
although our analysis may have been underpowered to
find association for the remaining two sub-specificities.
Additional factors directly stimulating B cells to produce
antibodies, such as B cell activating factor (BAFF,
a.k.a. BLyS) [45] or type I IFN [46] might also play a
role, but were not analyzed here.
Historically, ELIspot has been the assay of choice to
enumerate and visualize antigen-specific B cells, and
represents a very sensitive assay system. More recently,
the wish to isolate the antigen-specific B cells has led to
development of complementary technologies based on
flow cytometry. One setup is based on antigens being
coupled to beads and then used to stain B cells [47], and
in another setup large antigens could be directly coupled
to fluorochromes and used as staining reagents [48, 49];
last, for peptide-antigens, tetramerization of biotinylated
peptides before labeling to create so-called B cell tetra-
mers has been utilized [50]. The parallel use of a decoy
tetramer allows the purging of false-positive events
making this technology robust, and this approach has
already been employed to study cit-specific B cells in RA
[51, 52].
Utilizing B cell tetramer technology in the present
study, we were able to identify cit-Fib reactive B cells in
patients with RA and with a trend to higher frequency
in PTPN22 risk allele carriers. Though the data were not
statistically significant and were limited by there being
few data points (frozen cohort, n = 5 and fresh cohort, n
= 10), nevertheless they show a trend that was reprodu-
cible in two independent analyses (frozen and fresh co-
hort). This is in line with previous observations showing
the presence of more autoreactive B cells in PTPN22
risk allele carriers with RA and type-1 diabetes mellitus
[31]. In this study we used pooled tetramers from the
four cit-Fib antigens, because the limited availability of
cells from each patient did not allow us to use them sep-
arately. Therefore, our data do not provide informa-
tion on the relative number of the different cit-Fib
Joshua et al. Arthritis Research & Therapy  (2016) 18:284 Page 7 of 9
reactive B cells in each patient sample. Clearly, the
technology can also be utilized to study more com-
mon ACPA specificities in RA, but that was outside
the scope of this study.
Conclusion
In this study we have extended the family of ACPA target-
ing citrullinated fibrinogen. Four minor B cell epitopes on
the alpha chain of fibrinogen were validated, and patients
with RA displayed mainly non-overlapping immune re-
activity to these. The RA genetic risk factor PTPN22 was
associated with the new cit-Fib reactivity. We also demon-
strated the feasibility of visualizing antigen-specific B cells
by tetramer technology, which opens up the path for isola-
tion and further characterization of the autoimmune B
cells response in RA.
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